Cardio-protective effect of dapagliflozin against doxorubicin induced cardiomyopathy in rats

Belen E., Canbolat I. P., Yigitturk G., Cetinarslan O., Akdeniz C. S., Karaca M., ...More

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol.26, no.12, pp.4403-4408, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 12
  • Publication Date: 2022
  • Doi Number: 10.26355/eurrev_202206_29079
  • Journal Name: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.4403-4408
  • Keywords: Dapagliflozin, Doxorubicin, Cardiomyopathy, GROWTH-FACTOR 21, HEART
  • Istanbul University Affiliated: No

Abstract

OBJECTIVE: Cancer is the second most common non-communicable disease group in the world and its frequency is increasing. In parallel, side effects of drugs used in cancer treatment are frequently encountered. Doxorubicin (DOX) is one of the most effective multi-purpose anticancer drugs. However, its use is significantly limited due to the risk of cardiotoxicity. Sodium-glucose cotransporter-2 inhibitors are a group of antidiabetic drugs that have been shown to reduce cardiovascular events. Our aim is to examine the preventive effect of dapagliflozin on DOX-induced cardiac damage.